288 filings
10-Q
2024 Q1
ITCI
Intra-Cellular Therapies Inc
Quarterly report
7 May 24
7:43am
8-K
ITCI
Intra-Cellular Therapies Inc
7 May 24
Intra-cellular Therapies Reports First Quarter 2024 Financial Results
7:40am
ARS
2023 FY
ITCI
Intra-Cellular Therapies Inc
29 Apr 24
Annual report to shareholders
4:48pm
DEFA14A
ITCI
Intra-Cellular Therapies Inc
29 Apr 24
Additional proxy soliciting materials
4:46pm
DEF 14A
ITCI
Intra-Cellular Therapies Inc
Definitive proxy
29 Apr 24
4:06pm
8-K
r998lapb
24 Apr 24
Other Events
4:20pm
8-K
q2yc7hlp2 9hhrz64eg
18 Apr 24
Entry into a Material Definitive Agreement
5:25pm
424B5
of3u1y d1rwh
18 Apr 24
Prospectus supplement for primary offering
5:23pm
8-K
w64psa9f9171b45n5x6c
16 Apr 24
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:40pm
424B5
b1wuocki ms
16 Apr 24
Prospectus supplement for primary offering
4:37pm
S-3ASR
2ltbat6u
16 Apr 24
Automatic shelf registration
4:01pm
8-K
juqvsvekcsj4b3yb3e
16 Apr 24
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
7:10am
8-K
573uy tkr
1 Apr 24
Other Events
5:15pm
8-K
7tq1o4cct0lg37o9vp8
19 Mar 24
Intra-cellular Therapies Announces Executive Appointments and Leadership Changes
8:44am
8-K
7r19hf
22 Feb 24
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Corporate Update
7:39am
8-K
zh1dwzjjz26
2 Nov 23
Intra-cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
8:01am
8-K
4tap rzvchuzh9p23
3 Aug 23
Intra-cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
7:39am